Erectile Dysfunction in Patients With Coronary Artery Disease

Recent studies suggest that erectile dysfunction (ED) may be an early marking of endothelial dysfunction and coronary thoroughfare disease (CAD). Conversely, patients with CAD commonly have ED. The phosphodiesterase 5 (PDE5) inhibitors are very effective for the discussion of ED in patients with CAD. Numerous studies show that this teaching of drugs is in full general safe in patients with stable CAD and these agents do not exacerbate ischemia in men with CAD undergoing grooming tension experiment. Psychotherapy of placebo-controlled trials did not show an indefinite quantity in cardiovascular events among men receiving PDE5 inhibitors, and post-marketing surveillance studies with cheap sildenafil did not observe an amount in cardiovascular events compared to expected age-matched rates. Organic nitrates remain a contraindication for PDE5 inhibitors and letter of the alphabet blockers have precautions/contraindications depending upon particular drugs. The Princeton University Consensus Guidelines (soon to be updated) suggest a logical conceptualization to the semantic role with CAD attempt therapy for sexual dysfunction.